(Q80059427)

English

Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)

scientific article published on 28 March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

phase II clinical trial

1 reference

based on heuristic

inferred from title

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Jennifer J Knox

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sebastien J Hotte

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Christian Kollmannsberger

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Eric Winquist

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Bryn Fisher

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Elizabeth A Eisenhauer

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

28 March 2007

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Investigational New Drugs

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

471-477

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17393073%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

https://scigraph.springernature.com/pub.10.1007/s10637-007-9044-9

0 references

Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2004

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multinomial phase II cancer trials incorporating response and early progression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis and antitumor activity of 4- and 5-substituted derivatives of isoquinoline-1-carboxaldehyde thiosemicarbazone

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multinomial phase II trial designs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Application of a new multinomial phase II stopping rule using response and early progression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy directed at the components of nucleoside diphosphate reductase

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17393073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80059427&oldid=2005233816"